Skip to main content
Access Resources

MJFF Publications

6671 - 6680 of 7540 Results
Title
Year
  • Year
  • 2014
  • 2014
  • 2014
  • 2014
  • 2014
  • 2014
  • 2014
  • 2014
  • 2014
  • 2014
  • RESTRICTED
    Title: Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2013.08.008
    Citation Count: 29
  • RESTRICTED
    Title: Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(13)70293-x
    Citation Count: 547
  • RESTRICTED
    Title: Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats
    Journal Name: Neuropharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuropharm.2013.09.017
    Citation Count: 56
  • RESTRICTED
    Title: Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury
    Journal Name: Alzheimer's & Dementia
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.jalz.2013.12.011
    Citation Count: 61
  • RESTRICTED
    Title: Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease
    Journal Name: JAMA Neurology
    Publisher: American Medical Association (AMA)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1001/jamaneurol.2013.5528
    Citation Count: 200
  • RESTRICTED
    Title: Oxidation-induced Structural Changes of Ceruloplasmin Foster NGR Motif Deamidation That Promotes Integrin Binding and Signaling
    Journal Name: Journal of Biological Chemistry
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1074/jbc.m113.520981
    Citation Count: 28
  • RESTRICTED
    Title: Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2013.09.019
    Citation Count: 71
  • RESTRICTED
    Title: The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.nbd.2013.09.021
    Citation Count: 15
  • RESTRICTED
    Title: Treatment of Psychosis and Dementia in Parkinson’s Disease
    Journal Name: Current Treatment Options in Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1007/s11940-013-0281-2
    Citation Count: 105
  • RESTRICTED
    Title: Clinical Comparison of 99mTc Exametazime and 123I Ioflupane SPECT in Patients with Chronic Mild Traumatic Brain Injury
    Journal Name: PLoS ONE
    Publisher: Public Library of Science (PLoS)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1371/journal.pone.0087009
    Citation Count: 13
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.